COMT Polymorphism and Entacapone Efficacy

Summary

COMT Polymorphism and Entacapone Efficacy is a clinical trial^[1].

Key Facts

• COMT Polymorphism and Entacapone Efficacy is in the country of France^[2].
• COMT Polymorphism and Entacapone Efficacy's instance of is recorded as clinical trial^[3].
• COMT Polymorphism and Entacapone Efficacy's start time is recorded as +2006-10-31T00:00:00Z^[4].
• COMT Polymorphism and Entacapone Efficacy's end time is recorded as +2009-11-30T00:00:00Z^[5].
• COMT Polymorphism and Entacapone Efficacy's sponsor is recorded as Assistance Publique – Hôpitaux de Paris^[6].
• COMT Polymorphism and Entacapone Efficacy's main subject is recorded as Parkinson's disease^[7].
• COMT Polymorphism and Entacapone Efficacy's number of participants is recorded as {'unit': '1', 'amount': '+60'}^[8].
• COMT Polymorphism and Entacapone Efficacy's title is recorded as Influence of Catechol-O-methyltransferase Polymorphism on Entacapone Efficacy in Parkinson's Disease^[9].
• COMT Polymorphism and Entacapone Efficacy's short name is recorded as COMT^[10].
• COMT Polymorphism and Entacapone Efficacy's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+30'}^[11].
• COMT Polymorphism and Entacapone Efficacy's ClinicalTrials.gov ID is recorded as NCT00373087^[12].
• COMT Polymorphism and Entacapone Efficacy's research intervention is recorded as levodopa^[13].
• COMT Polymorphism and Entacapone Efficacy's research intervention is recorded as entacapone^[14].
• COMT Polymorphism and Entacapone Efficacy's clinical trial phase is recorded as phase IV clinical trial^[15].
• COMT Polymorphism and Entacapone Efficacy's research subject recruitment status is recorded as completed^[16].
• COMT Polymorphism and Entacapone Efficacy's study type is recorded as interventional study^[17].